ny-eso-1 protein
Vaccineexperimental
Clinical trial activity
2 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2010 (NCT01079741)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Tumor antigensImmunity, active
immunity, active - tumor antigen
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ny-eso-1 protein
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02833506 | Phase 1 | Jul 15, 2017 | National Cancer Institute (NCI), State University of New York, Buffalo |
| NCT01079741 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2010 | Cancer Research Institute, Icahn School of Medicine at Mount Sinai, Ludwig Institute for Cancer Research, New York University, Oncovir, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cancer Research Institute | Academic/Hospital | 1 | 0 | 1 | 2010 |
| Icahn School of Medicine at Mount Sinai | Academic/Hospital | 1 | 1 | 1 | 2010 |
| Ludwig Institute for Cancer Research | Academic/Hospital | 1 | 0 | 1 | 2010 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2017 |
| New York University | Academic/Hospital | 1 | 0 | 1 | 2010 |
| Oncovir, Inc. | For profit | 1 | 0 | 1 | 2010 |
| State University of New York, Buffalo | Academic/Hospital | 1 | 1 | 1 | 2017 |
7 organizations
Page 1 / 1